Latest Articles
XBP1 promoted EMT and fibrosis in endometrial epithelial cells. (a)... - researchgate.net
XBP1 promoted EMT and fibrosis in endometrial epithelial cells. (a)... researchgate.net
Published: July 9, 2025, 7:31 p.m.
Radiomics analysis based on T2-weighed imaging and T2 mapping for staging endometrial fibrosis - Nature
Radiomics analysis based on T2-weighed imaging and T2 mapping for staging endometrial fibrosis Nature
Published: July 8, 2025, 9:36 a.m.
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - Nature
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion Nature
Published: July 2, 2025, 5:48 a.m.
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion - nature.com
XBP1 promotes endometrial fibrosis through cGAS-STING signaling pathway in intrauterine adhesion nature.com
Published: July 2, 2025, 5:48 a.m.
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told - The Malaysian Reserve
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told The Malaysian Reserve
Published: June 26, 2025, 10:51 a.m.
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told - StreetInsider
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told StreetInsider
Published: June 25, 2025, 10:14 a.m.
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told - Morningstar
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told Morningstar
Published: June 25, 2025, 10 a.m.
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health
Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
Link copied to clipboard!